These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

822 related items for PubMed ID: 27799360

  • 1. Androgen receptor signaling in castration-resistant prostate cancer: a lesson in persistence.
    Coutinho I, Day TK, Tilley WD, Selth LA.
    Endocr Relat Cancer; 2016 Dec; 23(12):T179-T197. PubMed ID: 27799360
    [Abstract] [Full Text] [Related]

  • 2. Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level.
    Karantanos T, Evans CP, Tombal B, Thompson TC, Montironi R, Isaacs WB.
    Eur Urol; 2015 Mar; 67(3):470-9. PubMed ID: 25306226
    [Abstract] [Full Text] [Related]

  • 3. Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistance.
    Crona DJ, Milowsky MI, Whang YE.
    Clin Pharmacol Ther; 2015 Dec; 98(6):582-9. PubMed ID: 26331358
    [Abstract] [Full Text] [Related]

  • 4. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
    Shafi AA, Yen AE, Weigel NL.
    Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
    [Abstract] [Full Text] [Related]

  • 5. Targeting androgen receptor versus targeting androgens to suppress castration resistant prostate cancer.
    Guo C, Yeh S, Niu Y, Li G, Zheng J, Li L, Chang C.
    Cancer Lett; 2017 Jul 01; 397():133-143. PubMed ID: 28323036
    [Abstract] [Full Text] [Related]

  • 6. Androgen Receptor Rearrangement and Splicing Variants in Resistance to Endocrine Therapies in Prostate Cancer.
    Ho Y, Dehm SM.
    Endocrinology; 2017 Jun 01; 158(6):1533-1542. PubMed ID: 28368512
    [Abstract] [Full Text] [Related]

  • 7. Targeting persistent androgen receptor signaling in castration-resistant prostate cancer.
    Graham L, Schweizer MT.
    Med Oncol; 2016 May 01; 33(5):44. PubMed ID: 27042852
    [Abstract] [Full Text] [Related]

  • 8. Targeting the androgen receptor signaling pathway in advanced prostate cancer.
    Chung C, Abboud K.
    Am J Health Syst Pharm; 2022 Jul 22; 79(15):1224-1235. PubMed ID: 35390118
    [Abstract] [Full Text] [Related]

  • 9. Resistance to Hormonal Therapy in Prostate Cancer.
    Berruti A, Dalla Volta A.
    Handb Exp Pharmacol; 2018 Jul 22; 249():181-194. PubMed ID: 28353036
    [Abstract] [Full Text] [Related]

  • 10. Androgen receptor splicing variant 7: Beyond being a constitutively active variant.
    Shao C, Yu B, Liu Y.
    Life Sci; 2019 Oct 01; 234():116768. PubMed ID: 31445027
    [Abstract] [Full Text] [Related]

  • 11. Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer.
    Martin SK, Kyprianou N.
    Adv Cancer Res; 2015 Oct 01; 127():123-58. PubMed ID: 26093899
    [Abstract] [Full Text] [Related]

  • 12. Expanding androgen- and androgen receptor signaling-directed therapies for castration-resistant prostate cancer.
    Bastos DA, Dzik C, Rathkopf D, Scher HI.
    Oncology (Williston Park); 2014 Aug 01; 28(8):693-9. PubMed ID: 25140626
    [Abstract] [Full Text] [Related]

  • 13. Androgen receptor splice variants in the era of enzalutamide and abiraterone.
    Nakazawa M, Antonarakis ES, Luo J.
    Horm Cancer; 2014 Oct 01; 5(5):265-73. PubMed ID: 25048254
    [Abstract] [Full Text] [Related]

  • 14. ASC-J9(®) suppresses castration resistant prostate cancer progression via degrading the enzalutamide-induced androgen receptor mutant AR-F876L.
    Wang R, Lin W, Lin C, Li L, Sun Y, Chang C.
    Cancer Lett; 2016 Aug 28; 379(1):154-60. PubMed ID: 27233475
    [Abstract] [Full Text] [Related]

  • 15. Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer.
    Wadosky KM, Koochekpour S.
    Oncotarget; 2016 Sep 27; 7(39):64447-64470. PubMed ID: 27487144
    [Abstract] [Full Text] [Related]

  • 16. Prior long response to androgen deprivation predicts response to next-generation androgen receptor axis targeted drugs in castration resistant prostate cancer.
    Loriot Y, Eymard JC, Patrikidou A, Ileana E, Massard C, Albiges L, Di Palma M, Escudier B, Fizazi K.
    Eur J Cancer; 2015 Sep 27; 51(14):1946-52. PubMed ID: 26208462
    [Abstract] [Full Text] [Related]

  • 17. Role of androgen receptor splice variants, their clinical relevance and treatment options.
    Wach S, Taubert H, Cronauer M.
    World J Urol; 2020 Mar 27; 38(3):647-656. PubMed ID: 30659302
    [Abstract] [Full Text] [Related]

  • 18. Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis.
    Yuan X, Cai C, Chen S, Chen S, Yu Z, Balk SP.
    Oncogene; 2014 May 29; 33(22):2815-25. PubMed ID: 23752196
    [Abstract] [Full Text] [Related]

  • 19. Comprehensive Profiling of the Androgen Receptor in Liquid Biopsies from Castration-resistant Prostate Cancer Reveals Novel Intra-AR Structural Variation and Splice Variant Expression Patterns.
    De Laere B, van Dam PJ, Whitington T, Mayrhofer M, Diaz EH, Van den Eynden G, Vandebroek J, Del-Favero J, Van Laere S, Dirix L, Grönberg H, Lindberg J.
    Eur Urol; 2017 Aug 29; 72(2):192-200. PubMed ID: 28104311
    [Abstract] [Full Text] [Related]

  • 20. ErbB2 Signaling Increases Androgen Receptor Expression in Abiraterone-Resistant Prostate Cancer.
    Gao S, Ye H, Gerrin S, Wang H, Sharma A, Chen S, Patnaik A, Sowalsky AG, Voznesensky O, Han W, Yu Z, Mostaghel EA, Nelson PS, Taplin ME, Balk SP, Cai C.
    Clin Cancer Res; 2016 Jul 15; 22(14):3672-82. PubMed ID: 26936914
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 42.